2nd Quarter - Report

VIROPHARMA INCORPORATED for VIROPHARMA INCORPORATED

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$140,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report (this page) Jul 20, 2012 $140,000 Replaced
2nd Quarter - Amendment Oct 26, 2012 $120,000 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

340B Drug Pricing Program, accelerated approval, antibiotic incentives, bioequivalence of locally acting drugs, drug safety/supply chain integrity, drug shortages, essential health benefits, Medicaid coverage, Medicare coverage and reimbursement, and Orphan Drug Act.

LobbyistCovered position, as disclosed
JOHN EDWARD GREISSING —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.